• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小分子对心血管疾病的重大影响。

Small Molecules with Big Impacts on Cardiovascular Diseases.

机构信息

Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Biochem Genet. 2020 Jun;58(3):359-383. doi: 10.1007/s10528-020-09948-z. Epub 2020 Jan 29.

DOI:10.1007/s10528-020-09948-z
PMID:31997044
Abstract

Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Although in recent years there has been a significant progress in the diagnosis, treatment, and prognosis of CVD, but due to their complex pathobiology, developing novel biomarkers and therapeutic interventions are still in need. MicroRNAs (miRNAs) are a fraction of non-coding RNAs that act as micro-regulators of gene expression. Mounting evidences over the last decade confirmed that microRNAs were deregulated in several CVDs and manipulating their expression could affect homeostasis, differentiation, and function of cardiovascular system. Here, we review the current knowledge concerning the roles of miRNAs in cardiovascular diseases with more details on cardiac remodeling, arrhythmias, and atherosclerosis. In addition, we discuss the latest findings on the potential therapeutic applications of miRNAs in cardiovascular diseases.

摘要

心血管疾病(CVDs)是全球发病率和死亡率的主要原因。尽管近年来在 CVD 的诊断、治疗和预后方面取得了重大进展,但由于其复杂的病理生物学,仍然需要开发新的生物标志物和治疗干预措施。microRNAs(miRNAs)是一类非编码 RNA,作为基因表达的微调节剂。过去十年中的大量证据证实,几种 CVD 中存在 microRNAs 的失调,并且操纵它们的表达可以影响心血管系统的内稳态、分化和功能。在这里,我们详细回顾了 miRNAs 在心脏重构、心律失常和动脉粥样硬化等心血管疾病中的作用的最新知识。此外,我们还讨论了 miRNAs 在心血管疾病中的潜在治疗应用的最新发现。

相似文献

1
Small Molecules with Big Impacts on Cardiovascular Diseases.小分子对心血管疾病的重大影响。
Biochem Genet. 2020 Jun;58(3):359-383. doi: 10.1007/s10528-020-09948-z. Epub 2020 Jan 29.
2
miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges.miRNAs 在心血管疾病中的作用:潜在的生物标志物、治疗靶点及挑战
Acta Pharmacol Sin. 2018 Jul;39(7):1073-1084. doi: 10.1038/aps.2018.30. Epub 2018 Jun 7.
3
MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases.微小RNA作为心血管疾病的候选药物靶点
Curr Drug Targets. 2017;18(4):463-472. doi: 10.2174/1389450117666160301101221.
4
MicroRNAs: roles in cardiovascular development and disease.微小 RNA:在心血管发育和疾病中的作用。
Cardiovasc Pathol. 2021 Jan-Feb;50:107296. doi: 10.1016/j.carpath.2020.107296. Epub 2020 Oct 3.
5
Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases.microRNAs、长链非编码 RNAs 和环状 RNAs 在心血管疾病中的临床意义。
Cells. 2023 Jun 14;12(12):1629. doi: 10.3390/cells12121629.
6
MicroRNA and Cardiovascular Diseases.微小 RNA 与心血管疾病。
Balkan Med J. 2020 Feb 28;37(2):60-71. doi: 10.4274/balkanmedj.galenos.2020.2020.1.94. Epub 2020 Feb 5.
7
Circulating miRNAs as biomarkers in cardiovascular diseases.循环 miRNA 作为心血管疾病的生物标志物。
Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2234-2243. doi: 10.26355/eurrev_201903_17271.
8
Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases.循环微小RNA在心血管疾病中的诊断、预后及治疗作用
Heart Lung Circ. 2014 Jun;23(6):503-10. doi: 10.1016/j.hlc.2014.01.001. Epub 2014 Mar 16.
9
Non-coding RNAs regulating mitochondrial function in cardiovascular diseases.非编码 RNA 调控心血管疾病中线粒体功能。
J Mol Med (Berl). 2023 May;101(5):501-526. doi: 10.1007/s00109-023-02305-8. Epub 2023 Apr 4.
10
Role of miRNAs on the Pathophysiology of Cardiovascular Diseases.微小RNA在心血管疾病病理生理学中的作用。
Arq Bras Cardiol. 2018 Nov;111(5):738-746. doi: 10.5935/abc.20180215.

引用本文的文献

1
Research hotspots and development trends of microRNA in ischemia-reperfusion: network analysis of academic journals oriented by bibliometric and visualization.缺血再灌注中微小RNA的研究热点与发展趋势:基于文献计量学和可视化的学术期刊网络分析
Ann Transl Med. 2022 Dec;10(24):1321. doi: 10.21037/atm-22-5677.
2
Bioinformatics Analysis to Find Novel Biomarkers for Coronary Heart Disease.寻找冠心病新型生物标志物的生物信息学分析
Iran J Public Health. 2022 May;51(5):1152-1160. doi: 10.18502/ijph.v51i5.9430.
3
First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 Inhibitor.
首次发现小白菊内酯具有抑制 NPC1L1 的降胆固醇活性。
Molecules. 2022 Sep 23;27(19):6270. doi: 10.3390/molecules27196270.
4
Circular RNAs: New Players in Cardiomyopathy.环状 RNA:心肌病的新角色。
Genes (Basel). 2022 Aug 26;13(9):1537. doi: 10.3390/genes13091537.
5
Molecular mechanisms of isoflavone puerarin against cardiovascular diseases: What we know and where we go.异黄酮葛根素抗心血管疾病的分子机制:我们所知与前行方向
Chin Herb Med. 2022 Mar 23;14(2):234-243. doi: 10.1016/j.chmed.2021.12.003. eCollection 2022 Apr.
6
Tenascin-C as a noninvasive biomarker of coronary artery disease.Tenascin-C 作为冠状动脉疾病的一种非侵入性生物标志物。
Mol Biol Rep. 2022 Oct;49(10):9267-9273. doi: 10.1007/s11033-022-07760-z. Epub 2022 Aug 8.
7
Post-Transcriptional Effects of miRNAs on PCSK7 Expression and Function: miR-125a-5p, miR-143-3p, and miR-409-3p as Negative Regulators.微小RNA对前蛋白转化酶枯草溶菌素9(PCSK7)表达和功能的转录后效应:miR-125a-5p、miR-143-3p和miR-409-3p作为负调控因子
Metabolites. 2022 Jun 23;12(7):588. doi: 10.3390/metabo12070588.
8
EpisomiR, a New Family of miRNAs, and Its Possible Roles in Human Diseases.EpisomiR,一种新的微小RNA家族及其在人类疾病中的可能作用。
Biomedicines. 2022 May 30;10(6):1280. doi: 10.3390/biomedicines10061280.
9
Mutational Spectrum of and Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia.在患有早发性冠状动脉疾病和家族性高胆固醇血症的伊朗患者中鉴定出的[具体基因名称1]和[具体基因名称2]基因的突变谱
Front Genet. 2021 Feb 11;12:625959. doi: 10.3389/fgene.2021.625959. eCollection 2021.
10
MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target.心血管疾病中的MiR-223-3p:一种生物标志物和潜在治疗靶点
Front Cardiovasc Med. 2021 Jan 20;7:610561. doi: 10.3389/fcvm.2020.610561. eCollection 2020.